AstraZeneca Investor Conference Presentation Deck
AstraZeneca: positioned to deliver industry-leading growth
Optimised LoE profile
Mid- and long-term durability
Ultom iris
Dato-Dxd
En hertu
Tagrisso
Calquence
Imfinzi
Lynparza
Soliris
Farxiga
Brilinta
2020
2025
2030
Growth from robust portfolio and an innovative pipeline
All growth rates at CER¹
Low twenties %
increase in 2022
1
2021
2022
2021-2025 low
double digit
CAGR²
2025
Total Revenue from COVID-19 medicines in 2021 and 2022
Industry-leading
growth post 2025
Managed LOE
• Diversified portfolio
• Transition to next
generation medicines
13
1. Constant Exchange Rates. 2. CAGR = compound annual growth rate. Double-digit CAGR of non-COVID-19 Total Revenue from 2021 (Alexion proforma) to 2025, assuming Constant Exchange Rates.
Pipeline
• Indication expansion
Geographic expansion
• Future launches of NMES
with validated mechanisms
Bar charts are illustrative only, not to scale
BView entire presentation